



UNAUDITED CONDENSED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS
FOR THE THREE MONTHS AND NINE MONTHS ENDED
SEPTEMBER 30, 2021
(EXPRESSED IN CANADIAN DOLLARS)

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these interim consolidated financial statements in accordance with standards established by the CPA Canada for a review of interim financial statements by an entity's auditor.

Leveljump Healthcare Corp.
 Unaudited Condensed Interim Consolidated Statement of Financial Position
 (Expressed in Canadian Dollars)

	As at	30-Sep-21	31-Dec-20
Assets			
Current Assets			
Cash and Cash Equivalents	\$	1,147,544	\$ 905,546
Accounts Receivable		620,112	562,099
Investments		136,500	-
Loans To Officers		373,021	-
Prepaid Expenses & Deposits		171,580	366,028
Receiver General		127,092	83,020
Total Current Assets		2,575,849	1,916,694
Right-Of-Use-Assets (Note 5)		26,159	50,706
Total Other Current Asset		2,602,008	1,967,399
Other Asset			
Deposits - BXU		250,100	-
Total Other Asset		250,100	-
Total Assets		2,852,108	1,967,399
Liabilities & Equity			
Current Liabilities			
Accounts Payable & Accrued Liabilities		729,329	1,006,949
Current Portion of Lease Liabilities (Note 8)		35,888	34,436
Due to Directors		694,150	340,114
Due to Related Party		-	49,063
Total Other Current Liability		1,459,368	1,430,562
Long Term Liability			
Lease Liabilities		-	26,585
Statute Barred Liabilities		222,327	123,152
Long Term-Debt (Note 7)			60,000
Total Long Term Liability		222,327	209,737
Total Liabilities		1,681,695	1,640,299
Equity			
Common Share Capital		11,675,222	10,981,422
Contributed Surplus		3,612,906	1,758,253
Deficit		(14,117,716)	(12,412,575)
Total Equity		1,170,412	327,100
Total Liabilities & Equity	\$	2,852,108	\$1,967,399

The accompanying notes are an integral part of these consolidated financial statements.

Nature of operations and going concern (Note 1)

Subsequent events (Note 15)

Approved on behalf of the Board:

(Signed) "Robert Landau" Director

(Signed) "Mitch Geisler" Director

Leveljump Healthcare Corp.
 Unaudited Condensed Interim Consolidated Statements of Income (Loss) and Comprehensive Income
 (Loss)
 (Expressed in Canadian Dollars)

As at	Three months ended		Nine months ended	
	30-Sep-21	30-Sep-20	30-Sep-21	30-Sep-20
Revenues				
Admin and Other Revenue	\$ 47,708	\$ 19,749	\$ 101,032	\$ 70,212
Teleradiology Revenue	1,691,757	1,498,626	4,823,527	3,903,277
Total Revenue	1,739,465	1,518,375	4,924,559	3,973,488
Cost of Sales				
Internet Connectivity	3,390	3,000	10,467	10,050
Medical Director Expenses	18,200	12,350	44,950	35,040
Medical Imaging Software	33,243	17,916	85,025	47,981
Reading Fees	1,328,386	1,198,901	3,799,012	3,121,658
Total Cost Of Goods Sold	1,383,219	1,232,167	3,939,454	3,214,730
Gross Profit	356,245	286,208	985,105	758,759
Expenses				
Advertising & Marketing	238,249	(138)	620,486	3,102
Amortization & Depreciation	8,183	8,183	24,548	24,548
General & Administrative	36,703	28,782	97,508	62,904
Insurance	30,238	7,217	73,856	15,086
Professional Fees	69,060	64,175	293,082	135,444
Rent	2,811	2,703	8,432	7,804
Salaries & Wages	320,614	92,327	923,551	280,187
Uncategorized Expense	-	-	-	(42,914)
Total Operating Expenses	705,858	203,248	2,041,463	486,162
Total Ordinary Income/Expense	(349,613)	82,960	(1,056,358)	272,597
Other Income/Expense				
Other Income				
Debt Forgiveness	-	-	20,000	-
Other Expense				
Finance Costs	2,495	16,903	8,742	50,061
Flow Capital Royalty	-	34,096	-	93,349
Foreign Exchange Gain/Loss	(5,432)	974	(1,481)	2,336
Other Miscellaneous Expense	(32,201)	22,788	(46,177)	21,625
Stock Based Compensation	104,732	-	707,753	-
Write-Off of A/P	-	-	(54)	-
Total Other Expense	69,594	74,761	668,783	167,372
Net Profit / (Loss)	(419,207)	8,199	(1,705,141)	105,224
Basic and diluted net comprehensive income (loss) per share	-	0.01	51.24	-
Weighted average common shares outstanding - basic and diluted			0.04	657.65
(Note 15)	50,933,921	160	45,896,470	160

The accompanying notes are an integral part of these consolidated financial statements.

Leveljump Healthcare Corp.
 Unaudited Condensed Interim Consolidated Statements of Changes of Cash Flows
 (Expressed in Canadian Dollars)

	Nine months ended	
	30-Sep-21	30-Sep-20
Operating activities		
Comprehensive income (loss)	\$ (1,705,141)	\$ 122,194
Adjustments for:		
Depreciation and Amortization	24,548	24,548
Credit Card for operating expenses	739	-
Interest accrued on director loan	-	4,559
Stock based compensation	707,753	-
	(972,101)	151,301
Changes in non-cash working capital items		
Accounts receivable	(58,012)	(34,777)
HST receivable/payable	(44,571)	(23,585)
Prepaid expenses and deposits	194,449	(15,553)
Accounts payable and accrued liabilities	76,880	41,808
Net cash (used in) provided by operating activities	\$ (803,356)	\$ 119,194
Investing Activities		
Investment in Subsidiaries	(386,600)	-
Net cash provided by (used in) investing activities	(386,600)	-
Financing Activities		
Advances to parent company	-	(90,168)
Loans from directors	-	(13,435)
Lease payments	(25,132)	(19,679)
Proceeds from Long Term Debt	-	40,000
Proceeds from Short term debt	-	25,000
Repayments of Long-term debt	(60,000)	(48,452)
Loans to directors	(373,021)	-
Advances (to)/from related party	(49,063)	-
Sale of common shares and warrants	1,840,700	-
Other current liability	98,470	-
Net cash provided by (used in) financing activities	\$ 1,431,953	\$ (106,734)
Increase/(Decrease) in cash	241,997	12,460
Cash (Bank Overdraft), beginning of period	\$ 905,546	\$ (2,103)
Cash (Bank Overdraft), end of period	\$ 1,147,544	\$ 10,357

The accompanying notes are an integral part of these consolidated financial statements.

Leveljump Healthcare Corp.
 Unaudited Condensed Interim Consolidated Statements of Changes in Equity
 (Expressed in Canadian Dollars)

	Common Share Capital		Contributed Surplus	Deficit Total Equity (Deficiency)	
	Number of common shares	Amount			
Balance, December 31, 2019	160	\$130,669	\$ -	\$ (849,533)	\$ (718,864)
Common shares and warrants issued for cash (Note 11)	8,700,511	2,679,758	1,235,472	-	3,915,230
Common shares and warrants issued pursuant to royalty buy	1,111,111	342,222	157,778	-	500,000
Share issuance costs	-	(471,527)	-	-	-471,527
Issuance of shares, warrants and options on RTO transaction	30,302,618	8,400,700	84,500	-	8,485,200
Shares and warrants issued to agents	250,000	77,000	35,500	-	112,500
Fair value of broker options issued to agents	-	(177,400)	177,400	-	-
Stock-based compensation	-	-	67,603	-	67,603
Net loss for the year	-	-	-	(11,563,042)	(11,563,042)
Balance, December 31, 2020	40,364,400	\$10,981,422	\$1,758,253	\$ (12,412,575)	\$ 327,100
Common shares issued	294,444	68,000	-	-	68,000
Stock-based compensation	-	-	392,758	-	392,758
Net loss for the quarter	-	-	-	(716,806)	(716,806)
Balance, March 31, 2021	40,658,844	\$11,049,422	\$2,151,011	\$ (13,129,381)	\$ 71,052
Common shares issued	10,002,000	1,500,800	-	-	1,500,800
Stock-based compensation	-	-	210,263	-	210,263
Issuance of warrants and options	-	(1,080,000)	1,115,400	-	35,400
Net loss for the quarter	-	-	-	(569,128)	(569,128)
Balance, June 30, 2021	50,660,844	\$11,470,222	\$3,476,674	\$ (13,698,509)	\$ 1,248,387
Common shares issued	600,000	205,000	-	-	205,000
Stock-based compensation	-	-	104,732	-	104,732
Issuance of warrants and options	-	-	31,500	-	31,500
Net loss for the quarter	-	-	-	(419,207)	(419,207)
Balance, September 30, 2021	51,260,844	11,675,222	\$3,612,906	\$ (14,117,716)	1,170,412

The accompanying notes to the consolidated financial statements are an integral part of these statements.

1. Nature of Operations and Going Concern

Leveljump Healthcare Corp. was incorporated as Good2Go2 Corp., (“G2G2”) under the Canada Business Corporations Act on March 21, 2019 (“Jump” or the “Company”).

The Company was classified as a Capital Pool Corporation, as defined in Policy 2.4 of the TSX Venture Exchange (the “Exchange”). The principal business of the Company was the identification and evaluation of assets or businesses with a view to completing a Qualifying Transaction (“QT”).

On July 15, 2020, the Company incorporated a wholly owned subsidiary, 12199483 Canada Inc., under the Canada Business Corporations Act, for the purpose of completing its QT with Canadian Teleradiology Services, Inc. (“CTS”).

On December 7, 2020, the Company closed its QT involving CTS wherein the Company acquired 100% of the issued and outstanding shares of CTS and began trading on the Exchange under the Symbol “JUMP”. These consolidated financial statements reflect the continuation of the financial position, operating results and cash flows of the Company’s legal subsidiary, CTS (see Reverse Take-Over Note 3).

The Company’s principal business activity is providing teleradiology services. Teleradiology is the process of providing remote off site reading of radiology scans such as CT, MRI, US, and X-ray. Hospital staff scan their emergency room patients, then page the Company’s radiologist on call, who can then remotely view, via secured server, the images and diagnose the patient and provide a report back to the hospital.

The Company's head office and registered office is located at 85 Scarsdale Road, Suite 304, Toronto, Ontario, M3B 2R2.

In March 2020, the World Health Organization declared coronavirus (COVID-19) a global pandemic. This contagious disease outbreak, which has continued to spread, has adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or ability to raise funds.

Going concern

These unaudited condensed interim consolidated financial statements have been prepared on a going concern basis which assumes the Company will continue in operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Accordingly, it does not give effect to adjustments, if any, that would be necessary should the Company be unable to continue as a going concern, and therefore be required to realize its assets and liquidate its liabilities in other than the normal course of business and at amounts that may differ from those shown in these unaudited condensed interim consolidated financial statements.

For the nine months ended September 30, 2021, the Company recorded a comprehensive loss of \$1,705,141. As at September 30, 2021, the Company had an accumulated deficit of \$14,117,716 (December 31, 2020: \$12,412,575). As at September 30, 2021, the Company had working capital of \$1,116,481 (December 31, 2020: \$486,130) These conditions raise material uncertainties which cast significant doubt as to whether the Company

will be able to continue as a going concern should it not be able to obtain the financing necessary to fund its planned revenue growth and working capital requirements.

The Company has raised funds throughout the prior and current fiscal years and has utilized these funds for working capital requirements. The ability of the Company to arrange additional financing in the future will depend in part upon the prevailing capital market conditions as well as the business performance of the Company. There can be no assurance that the Company will be successful in its efforts to arrange additional financing on terms satisfactory to the Company, nor achieve desired sales growth. If additional financing is raised by the issuance of common shares from treasury of the Company, control of the Company may change and existing shareholders may have their ownership diluted. If adequate funding is not available, the Company may be required to reduce its expansion and acquisition plans and even possibly reduce or terminate its operations.

2. Significant Accounting Policies

Basis of presentation

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34 - Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by the IASB.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRS issued and outstanding as of November 29, 2021, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements as at and for the year ended December 31, 2020. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ending December 31, 2021 could result in restatement of these unaudited condensed interim consolidated financial statements.

3. Reverse Take-Over

On July 15, 2020, the Company entered into a Business Combination Agreement ("BCA") with CTS under which a reverse acquisition transaction (the "Transaction") was contemplated. Under the terms of the BCA, the Company would acquire all the issued and outstanding common shares of CTS. Upon the BCA closing on December 7, 2020, the former CTS shareholders held approximately 91% of the outstanding shares of the Company. In substance, the Transaction involves former CTS shareholders obtaining control of the Company; accordingly, the Transaction is a reverse acquisition under which CTS is identified as the accounting acquirer. The future consolidated financial statements of the combined entity therefore represent the continuation of CTS.

G2G2 did not meet the definition of a business under IFRS 3 Business Combinations ("IFRS 3") prior to the Transaction. The Transaction is therefore accounted for in accordance with IFRS 2 Share-based Payment ("IFRS 2") whereby CTS is deemed to have issued shares in exchange for the net assets of G2G2 at the fair value of the consideration received by CTS.

Leveljump Healthcare Corp.
Notes to Unaudited Condensed Interim Consolidated Financial Statements
For the Three Months and Nine Months Ended September 30, 2021
(Expressed in Canadian Dollars)

As a result of this asset acquisition, a listing expense of \$8,749,541 has been recorded. This reflects the difference between the estimated fair value of consideration given is as follows:

Fair value of net assets acquired

Cash and cash equivalents	\$	210,802
Amounts receivable		13,700
Accounts payable and accrued liabilities		(143,021)
Listing expense		8,749,541
	\$	8,831,022

Consideration given

Common shares	\$	8,400,700
Stock options and warrants		84,500
Professional fees		345,822
	\$	8,831,022

4. Accounts Receivable

Accounts receivables are collectible from customer sales. The following is an aging analysis of the Company's trade and other receivables:

	Total Receivable	Aging Days			
		Current	31 to 60	61 to 90	90+
December 31, 2020	\$ 562,099	453,669	99,684	-	8,746
September 30, 2021	\$ 620,112	600,979	18,346	(169)	956

As at September 30, 2021 and December 31, 2020, no impairment was recorded for any portion of the trade receivables.

The Company held no collateral for any receivable amounts outstanding as of September 30, 2021 and December 31, 2020.

5. Right-of-use Assets

Balance, December 31, 2019	\$ 83,437
Amortization	(32,731)
Balance, December 31, 2020	\$50,706
Amortization	(24,547)
Balance, September 30, 2021	\$26,159

Right-of-use assets consist of office space and computers. Computers are amortized over 36 months and office space is amortized over 36 months.

6. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities of the Company are principally comprised of amounts outstanding for subcontracted radiologists and for other amounts relating to operating activities.

	September 30, 2021	December 31, 2020
Accounts Payable	\$629,107	\$ 921,681
Accrued Liabilities	100,222	85,268
	<u>\$729,329</u>	<u>\$ 1,006,949</u>

The standard maturity terms of the Company's accounts and other payables are 30 to 60 days.

7. Long Term Debt

The Company had a term loan from iCapital Financial Services Corp. ("iCapital") that was issued on December 5, 2018 for a principal amount of \$100,000 with a total cost of borrowing of \$43,000. On May 8, 2019, the Company borrowed an additional \$80,000 from iCapital with a total cost of borrowing of \$34,400. On December 15, 2020, the Company repaid the balances due on the loans from iCapital.

During the year ended December 31, 2020, the Company incurred interest of \$45,869 (2019 - \$34,245) on the loans from iCapital.

On April 17, 2020, the Company entered the Canada Emergency Business Account ("CEBA") loan with TD Canada Trust for \$40,000. The initial term of the loan is until December 31, 2022, and if paid in full by that time no interest will be due under the loan and the Company will only be required to pay back \$30,000. If the loan is not paid in full by December 31, 2022 it will convert into a three-year term loan with interest at 5%.

On December 30, 2020, the Company received the CEBA extension loan of \$20,000 so the full CEBA loan now has a balance of \$60,000, and if paid back by December 31, 2022 only \$40,000 will need to be repaid.

On May 10, 2021 the Company repaid the required \$40,000 CEBA amount and the loan is now discharged.

8. Lease Liabilities

The Company's leases end in July and August 2022. The aggregate lease payment is \$3,732/month.

On August 1, 2019, the Company entered into a lease agreement with Capitol Building Properties with respect to its head office location. The lease expires on July 31, 2022.

On August 12, 2019, the Company entered into a lease agreement with Dell, with respect to two computer servers. The lease expires on August 11, 2022.

June 30, 2021 December 31, 2020

Leveljump Healthcare Corp.
Notes to Unaudited Condensed Interim Consolidated Financial Statements
For the Three Months and Nine Months Ended September 30, 2021
(Expressed in Canadian Dollars)

Current Portion	\$35,888	\$ 34,436
Non-current Portion	-	26,585
	\$ 35,888	\$ 61,021

9. Common Share Capital

Authorized Share Capital

Unlimited number of common shares, with no par value.

Common Shares Issued

	Number of common shares	Amount
Balance, December 31, 2019 and September 30, 2020	160	\$130,653
Balance, December 31, 2020	40,364,400	\$ 10,981,422
Exercise of warrants (a)	125,000	22,500
Exercise of options (b)	44,444	8,000
Shares issued for debt (c)	125,000	37,500
Balance, March 31, 2021	40,658,844	\$ 11,049,422
Shares issued for private placement (d)	10,000,000	1,500,000
Shares issued for debt (e)	2,000	800
Balance, June 30, 2021	50,660,844	\$ 11,470,222
Shares issued for private placement (f)	250,000	100,000
Shares issued for Shaw Lens and Shaw Vision investment (g)	350,000	105,000
Balance, September 30, 2021	51,260,844	\$ 11,675,222

(a) On January 22, 2021, 125,000 warrants were exercised for gross proceeds of \$22,500.

(b) On March 11, 2021, 44,000 options were exercised for gross proceeds of \$8,000.

(c) On February 8, 2021, 125,000 units, consisting of 1 common share and 1 warrant to purchase a common share at a price of \$0.20 good until March 31, 2024, in exchange for debt of \$37,500.

(d) On May 12, 2021, 10,000,000 units, consisting of 1 common share and 1 warrant to purchase a common share at a price of \$0.20 good until March 31, 2024, were issued as part of a non-brokered private placement for proceeds of \$1,500,000. The fair value of the warrants granted is estimated at \$1,080,000 using the Black-Scholes model for option pricing. The assumptions underlying the fair value of the share purchase options were as follows: risk free interest rate – 0.27%; dividend yield - 0%; expected stock volatility - 90% and a warrant life - 3 years.

- (e) On June 9, 2021, 2,000 shares were issued to employees in exchange for \$800 of bonuses.
- (f) On August 5, 2021, 250,000 shares were issued to an accredited investor at a price of \$0.40 per shares for total proceeds of \$100,000.
- (g) On August 30, 2021, 350,000 units, consisting of 1 common share and 1 warrant, good to purchase a common share at an exercise price of \$0.30 per share with an expiry of December 31, 2023, were issued at a deemed value of \$105,000. The units were issued in exchange for 23.8% ownership interest in each of Shaw Lens Inc. and Shaw Vision Inc.

10. Stock Options

The Company has a Share Option Plan (the "Plan") under which it is authorized to grant options to purchase common shares of the Company to directors, senior officers, employees and/or consultants of the Company. The aggregate number of shares of the Company which may be issued and sold under the Plan will not exceed 20% of the total number of common shares issued and outstanding as of the date of the RTO transaction. Share options are granted with a maximum term of ten years with vesting requirements at the discretion of the Board of Directors.

The Company records a charge to the statement of loss and comprehensive loss using the Black-Scholes fair valuation option pricing model with respect to a share option grant. The valuation is dependent on several estimates, including the risk-free interest rate, the level of share volatility, together with an estimate of the level of forfeiture. The level of share volatility is calculated with reference to the historic traded daily closing share price at the date of issue. Option pricing models require the input of highly subjective assumptions including the expected price volatility. Changes in the subjective input assumptions can materially affect the fair value estimate, and therefore the existing models do not necessarily provide a reliable measure of the fair value of the Company's share purchase options.

	Number of stock options	Weighted average exercise price
Balance, December 31, 2019 and September 30, 2020	-	\$ nil
Balance, December 31, 2020	4,245,555	0.43
Granted	-	-
Cancelled	-	-
Exercised (Note 9(b))	(44,000)	0.18
Balance, March 31, 2021	4,201,556	0.43
Granted (b)	200,000	0.25
Cancelled	(70,000)	0.45
Balance, June 30, 2021	4,331,112	0.42
Granted	-	-
Cancelled	-	-

Leveljump Healthcare Corp.
Notes to Unaudited Condensed Interim Consolidated Financial Statements
For the Three Months and Nine Months Ended September 30, 2021
(Expressed in Canadian Dollars)

Balance, September 30, 2021	4,331,112	0.42
------------------------------------	------------------	-------------

- (a) The portion of the estimated fair value of options granted in the prior year and vested during the three months ended September 30, 2021, amounted to \$104,732 (three months ended September 30, 2020 - \$nil).
- (b) The fair value of the stock options granted is estimated at \$35,400 using the Black-Scholes model for option pricing. The assumptions underlying the fair value of the share purchase options were as follows: risk free interest rate – 0.27%; dividend yield - 0%; expected stock volatility - 90% and an option life - 1 year.

The following table reflects the actual stock options issued and outstanding as of September 30, 2021:

Expiry date	Exercise price (\$)	Weighted average remaining contractual life (years)	Number of options outstanding	Number of options vested (exercisable)
12-Feb-25	0.18	3.41	47,222	47,222
07-Dec-21	0.18	0.25	188,889	188,889
21-Dec-23	0.45	2.25	3,895,000	2,300,000
19-May-22	0.25	0.50	200,000	200,000
	0.44	2.09	4,331,112	2,736,111

11. Warrants

The following table reflects the continuity of warrants for the three months ended September 30, 2021 and 2020:

	Number of Warrants	Weighted Average Exercise Price
Balance December 31, 2019 and September 30, 2020	-	\$ nil
Balance, December 31, 2020	10,186,622	0.50
Exercised (Note 9(a))	(125,000)	0.18
Granted (Note 9(c))	125,000	0.50
Cancelled	-	-
Balance, March 31, 2021	10,186,622	0.50
Granted (Note 9(d))	10,000,000	0.20
Balance, June 30, 2021	20,186,622	0.35
Granted (Note 9(g))	350,000	0.30
Balance, September 30, 2021	20,536,622	0.35

The following table reflects the warrants issued and outstanding as of December 31, 2020:

Expiry date	Exercise price (\$)	Warrants outstanding
December 13, 2023	\$0.50	10,186,622
March 31, 2024	\$0.20	10,000,000
December 31, 2023	\$0.30	350,000
	\$0.35	20,536,622

12. Broker Options

As part of the concurrent Financing completed prior to the RTO transaction, the Company was required to issue 696,040 Broker options of the Company. Each Broker option entitles the holder to purchase a Unit of the Company at a price of \$0.45 good for 3 years. Each Unit consists of one common share and one warrant to purchase one common share at a price of \$0.50, which expires on December 13, 2023. The fair value of the 696,040 broker options granted is estimated at \$177,400 using the Black-Scholes model for option pricing. The assumptions underlying the fair value of the share purchase options were as follows: risk free interest rate – 0.32%; dividend yield - 0%; expected stock volatility - 90% and an option life - 3 years.

13. Related Party Transactions

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. The following related party transactions were conducted in the normal course of operations and were made on an arm's length basis:

During the three months ended September 30, 2021, Chief Executive Officer ("CEO") salary for the quarter was \$120,000 (three months ended September 30, 2020 - \$60,000) of which \$64,615 was paid in cash and \$55,385 was accrued to be paid at a later date.

During the three months ended September 30, 2021, Chief Financial Officer ("CFO") salary for the quarter was \$120,000 (three months ended September 30, 2020 - \$60,000) of which \$64,615 was paid in cash and \$55,385 was accrued to be paid at a later date.

As at September 30th, 2021, the Company has loaned the CEO \$193,021 during the year, due on demand at 0% interest, with no pre-set terms of repayment and the Company owed the CEO \$417,431 in accrued salary and expenses.

As at September 30th, 2021, the Company has loaned the CFO \$183,000 during the year, due on demand at 0% interest, with no pre-set terms of repayment and the Company owed the CFO \$276,720 in accrued salary and expenses.

14. Royalty Expense

On October 1, 2018, CTS became party to the Amended and Restated Secured Royalty Purchase Agreement (the "Agreement") between CTS' then parent company, MEDD Medical Imaging Corp. ("MIC"), and Flow Capital Corp ("Flow"). The terms impacting CTS were as follows:

- Effective October 1, 2018, CTS will pay a gross sales royalty based on of 2.5% of its revenues or \$6,000 USD (whichever is greater) monthly to Flow.
- There was a cross-guarantee such that CTS will guarantee all royalty payments of MIC and vice-versa.
- Agreement secured by a general security agreement covering all the CTS' current and future assets.

As part of the RTO transaction and concurrent financing on December 7, 2020, CTS bought out all its obligations under the Agreement for \$2,000,000. The proceeds were paid as \$1,500,000 in cash from the proceeds of the concurrent financing and 1,111,111 in Subscription Receipts of the concurrent financing valued at \$500,000. Immediately prior to closing of the RTO each Subscription Receipt was deemed to be exercised without payment of any additional consideration and without further action on the part of the holders thereof, to receive one common share and one common share purchase warrant. Each common share purchase warrant entitled the holder thereof to acquire one common share at a price of \$0.50 per share for a period of thirty-six months.

As part of the Agreement buyout, officers of the Company and MIC agreed to swap their escrow allotment of shares for June 7, 2021 with Flow giving rise to a liability of \$546,000 for which they were reimbursed by the Company ("Share swap").

15. Subsequent Events

Unless disclosed elsewhere, the Company's subsequent events comprise the following:

On November 16, 2021, the Company signed an agreement to purchase Telehospital Corp. for a total purchase price of approximately US\$7.13 million. This will be paid to the vendors as follows; US\$100,000 to be paid as cash deposit upon the signing of definitive agreements, US\$4.9 million cash on closing, with US\$1 million of this amount held in escrow for 24 months, The Company will issue on closing to the vendors a three year US\$500,000 5% note which is convertible into common shares of the company at the rate of \$0.25 per common share, The Company will issue 4 million common shares to the vendors at a price of C\$0.20 per share to be released to the vendors at the rate of 25% on closing and 25% on each of the 6th, 12th, and 18th month after closing.

On November 24, 2021, the Company announced that it had purchased 14.6% minority investment in Real Time Medical in exchange for 2,494,576 units of the Company. Each unit will be issued at a price of \$0.66 per unit with each unit being comprised of three common shares at a deemed price of \$0.22 per share and one share purchase warrant of the Company. Each warrant entitles the holder to acquire one additional common share of Leveljump at the price of \$0.35 per common share on or before December 31, 2023

On November 25, 2021, the Company announced that TD Canada Trust has agreed to loan the Company \$3.2 million in a term loan amortized over 120 months, along with a \$150,000 line of credit at prime +1.5%, for the purposes of closing the Company's acquisition of three diagnostic imaging centers in eastern Ontario.